JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2022-11-08 祝我好运

JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间

59 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2022-07-03 1ddf3775m09(暂无匿称)

这个杂志送外审后拒稿概率大不大？

56 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2022-10-21 slientwo

JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。

49 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2020-09-09 豆豆家的刺猬

请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~

126 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2020-07-01 darktempler

刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了...

163 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2023-12-02 YYS9508 来自浙江省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受

32 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2022-07-10 marmalade

肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。

61 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2021-11-10 ms8000001335392378

请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review

80 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2020-11-30 ms2000000438166751

急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？

76 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2099083, encodeId=aeb8209908393, content=JECCR昨天晚上刚接收，请问有小伙伴知道多久可以online吗？因为马上要找工作了，所以比较关心online时间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=59, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaELz4jrEZgLqr5Eec2V9DMrPoBFjv0rrOnGDXsibA8ibd9ric0WRsVHOUoxMdNv3JESibAlYJes7tOK46g/132, createdBy=952e2441680, createdName=祝我好运, createdTime=Tue Nov 08 00:01:45 CST 2022, time=2022-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1230361, encodeId=4b651230361db, content=这个杂志送外审后拒稿概率大不大？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=56, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun Jul 03 22:16:55 CST 2022, time=2022-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2095095, encodeId=3b452095095a6, content=JECCR, molecular cancer, Theranostics，Journal of Hematology & Oncology四大国人极其友好型，数据堆砌型杂志。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=49, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Fri Oct 21 07:26:51 CST 2022, time=2022-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=884057, encodeId=78fb88405e82, content=请问各位大佬，该杂志修回被拒的概率大嘛？跪谢~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fee62100283, createdName=豆豆家的刺猬, createdTime=Wed Sep 09 23:46:55 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800788, encodeId=2425800e886d, content=刚投一篇就被秒拒，感觉现发的文章水平跟我的差不多，涨到七分牛气了..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=163, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKbUQVcNicMmoEngbhNsjHtgPVly9ibpH1ngtTSp4EjBLr38AKWnRaGSJRVPTfjNL7rlfd969jibvZaw/132, createdBy=793b1668391, createdName=darktempler, createdTime=Wed Jul 01 16:10:43 CST 2020, time=2020-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2172474, encodeId=e3e521e2474fe, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：投了2片，一篇秒拒，一篇外审2个月后小修，2个月后修回，接受, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/25/b822cea76f86c21288adfae363c6acee.jpg, createdBy=b6602342517, createdName=YYS9508, createdTime=Sat Dec 02 13:09:55 CST 2023, time=2023-12-02, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1231689, encodeId=8fab1231689df, content=肿瘤方向review，发投稿第二天reviewer assigned然后under review，目前半个月了。请问综述送审后被拒的概率大吗？向各位前辈请教经验。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=80631681802, createdName=marmalade, createdTime=Sun Jul 10 21:54:36 CST 2022, time=2022-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068901, encodeId=09c5106890183, content=请问大家一般major revise返修后，审多长时间呢？我这快两周了还是under review, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f4645542531, createdName=ms8000001335392378, createdTime=Wed Nov 10 09:42:40 CST 2021, time=2021-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903569, encodeId=596a9035697e, content=急！！！投稿整半月，仍然是new submission状态。有没有出现相同问题的哥们？要不要发邮件问一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427e5420707, createdName=ms2000000438166751, createdTime=Mon Nov 30 15:55:05 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2178595, encodeId=e50121e859507, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：肿瘤;代谢 经验分享：Editorial decision: Major revision On 05 Dec, 2023 Reviewers agreed On 06 Nov, 2023 Reviewers invited Invitations sent on 06 Nov, 2023 Editor assigned On 06 Nov, 2023 First submitted to Journal of Experimental & Clinical Cancer Research On 02 Nov, 2023 大修修回后7天接收。祝各位好运~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83er97icXiab4eLtvJug1TAxlt9CQ8EzLYVKlCtamiavIx3KBrCsmkLHNkoexMVZrR9xv53bibfVMn3ZbTg/132, createdBy=333c2520605, createdName=很纯的牛奶, createdTime=Mon Jan 01 14:32:16 CST 2024, time=2024-01-01, status=1, ipAttribution=吉林省)]

2024-01-01 很纯的牛奶来自吉林省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：肿瘤;代谢
经验分享：Editorial decision: Major revision
On 05 Dec, 2023
Reviewers agreed
On 06 Nov, 2023
Reviewers invited
Invitations sent on 06 Nov, 2023
Editor assigned
On 06 Nov, 2023
First submitted to Journal of Experimental & Clinical Cancer Research
On 02 Nov, 2023

大修修回后7天接收。祝各位好运~

21 4

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务